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RESUMEN 
 
Ventilación con presión positiva binivel espontánea /tiempo (BIPAP S/T) con presión de 
soporte garantizada con volumen medio (AVAPS) utiliza un volumen corriente que se ajusta 
automáticamente a las necesidades del paciente. Nuestro estudio evaluó el uso de BIPAP S/T 
con AVAPS en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y 
encefalopatía hipercápnica en comparación con solamente el uso de BIPAP S/T, luego de 
inmediata llegada a la UCI de Emergencia. Hicimos un estudio prospectivo intervencional de 
casos controles pareados en Guayaquil, Ecuador. Un total de 22 pacientes fueron analizados. 
Once  pacientes con exacerbación de EPOC y encefalopatía hipercápnica con Escala de coma 
de Glasgow (GCS), <10 y pH de 7.25-7.35 fueron asignados al grupo BIPAP s/T con 
AVAPS. Gasometría, GCS, signos vitales y parámetros respiratorios fueron medidos y 
comparados entre ambos grupos. Observamos diferencias estadísticamente significativas a 
favor de BIPAP-AVAPS en GCS (P= .00001), pCO2 (P = .03) and presión máxima positiva 
de la vía aérea (IPAP).  (P = .005), entre otros. Sin embargo no hubo diferencias 
significativas en términos de tiempo de estadía o días en NIV. BIPAP S/T con AVAPS 
facilita rápida recuperación de conciencia en comparación con BIPAP S/T tradicional en 
pacientes con EPOC + encefalopatía hipercápnica. 
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ABSTRACT 
Bilevel positive airway pressure-spontaneous/timed (BiPAP S/T) with average volume 
assured pressure support (AVAPS) uses a fixed tidal volume that automatically adjusts to a 
patient’s needs. Our study assessed the use of BiPAP S/T with AVAPS in patients with 
chronic obstructive pulmonary disease (COPD) and hypercapnic encephalopathy as 
compared to BiPAP S/T alone, upon immediate arrival in the Emergency-ICU. We carried 
out a prospective interventional match-controlled study in Guayaquil, Ecuador. A total of 22 
patients were analyzed. Eleven with COPD exacerbations and hypercapnic encephalopathy 
with a Glasgow Coma Scale (GCS) <10 and a pH of 7.25-7.35 were assigned to receive NIV 
via BiPAP S/T with AVAPS. Arterial blood gases, GCS, vital signs, and ventilatory 
parameters were then measured and compared between the two groups. We observed 
statistically significant differences in favor of the BiPAP S/T + AVAPS group in GCS (P= 
.00001), pCO2 (P = .03) and maximum inspiratory positive airway pressure (IPAP) (P = 
.005), among others. However, no significant differences in terms of length of stay or days on 
NIV were observed. BiPAP S/T with AVAPS facilitates rapid recovery of consciousness 
when compared to traditional BiPAP S/T in patients with chronic obstructive pulmonary 
disease and hypercapnic encephalopathy. 
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TABLES 
Table 1. Evolution of blood gases, vital signs, and ventilatory parameters (mean ± SD) 
Variables Groups Initial 1 hour 3 hours 12 hours P 
GSC 
 
BiPAP S/T 
 
8.3 ± 1.4 
 
9.7 ± 2 
 
12 ± 1.5 
 
13 ± 1 
 
.00001* 
 
BiPAP S/T + 
AVAPS 
 
8.3 ± 1.6 
 
11 ± 1 
 
14.1 ± 0.8 
 
15 ± 0 
 
pH 
 BiPAP S/T 
 
7.28 ± 0.02 
 
7.30 ± 
0.05 
 
7.31 ± 0.11 
 
7.32 ± 0.12 
 
.31 
 
BiPAP S/T + 
AVAPS 
 
7.29 ± 0.03 
 
7.34 ± 
0.04 
 
7.37 ± 0.11 
 
7.37 ± 0.08 
 
pCO2 
 
BiPAP S/T 
 
64.8 ± 9.1 
 
58.3 ± 8.7 
 
53.2 ± 9 
 
50.1 ± 6.5 
 
.03* 
 
BiPAP S/T + 
AVAPS 
 
63 ± 16.3 
 
50.7 ± 
11.2 
 
45.4 ± 7.9 
 
43.6 ± 6.5 
 
PO2 
 
BiPAP S/T 
 
66.6 ± 12.7 
 
83.1 ±17.8 
 
75.3 ± 26.7 
 
79.7 ± 16.2 
 
.31 
 
BiPAP S/T + 
AVAPS 
 
71.5 ± 16.8 
 
78 ± 19.1 
 
87.5 ± 11.5 
 
87.4 ± 18 
 
HCO3 
 
BiPAP S/T 
 
26.9 ± 5.7 
 
24.4 ± 6.3 
 
25.8 ± 4.6 
 
27.1 ± 4.3 
 
.19 
 
BiPAP S/T + 
AVAPS 
 
24.4 ± 5 
 
22.5 ± 3.5 
 
23.7 ± 5.2 
 
24.6 ± 4.3 
 
Base excess 
 
BiPAP S/T 
 
3.3 ± 6.9 
 
0.1 ± 7 
 
10.3 ± 31.7 
 
3.6 ± 4.7 
 
.06 
 
BiPAP S/T + 
AVAPS 
 
−1.8 ± 5.7 
 
2.8 ± 18 
 
5.7 ± 19.8 
 
2.9 ± 9 
 
Systolic blood pressure 
 BiPAP S/TS/T 
 
125.1 ± 10 
 
124.2 ± 
12.6 
 
130.4 ± 
14.3 
 
130.6 ± 
13.8 
 
.29 
 
BiPAP S/T + 
AVAPS 
 
125.9 ± 
17.3 
 
131.1 ± 
21.1 
 
129.9 ± 
18.4 
 
123.5 ± 
16.9 
 
Diastolic blood pressure 
 
BiPAP S/T 
 
73.9 ± 9.8 
 
72.2 ± 8.4 
 
71.8 ± 9.4 
 
73.7 ± 10.7 
 
.07 
 
BiPAP S/T + 
AVAPS 
 
65.5 ± 11.6 
 
69.8 ± 
11.6 
 
70.1 ± 11.1 
 
65.9 ± 8.5 
 
Heart rate BiPAP S/T 86.7 ± 9.1 82.1 ± 7.8 80.4 ± 5.8 79.1 ± 5.5 .07 
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Variables Groups Initial 1 hour 3 hours 12 hours P 
       
BiPAP S/T + 
AVAPS 
 
82 ± 10.9 
 
82.5 ± 9.9 
 
72.8 ± 14.1 
 
72. ± 11.2 
 
Respiratory rate 
 
BiPAP S/T 
 
27.9 ± 5.6 
 
23.2 ± 3.5 
 
21 ± 2.6 
 
20 ± 1.61 
 
.01* 
 
BiPAP S/T + 
AVAPS 
 
29 ± 6.9 
 
17.4 ± 3.2 
 
18.5 ± 3.6 
 
19.9 ± 5.1 
 
Maximum delivered IPAP 
received 
 
BiPAP S/T 
 
12.3 ± 0.9 
 
12.6 ± 0.9 
 
14.3 ± 0.8 
 
14.7 ± 1 
 
.005* 
 
BiPAP S/T + 
AVAPS 
 
19.8 ± 2.2 
 
18.3 ± 2.3 
 
18 ± 2.6 
 
17 ± 2.3 
 
EPAP 
 
BiPAP S/T 
 
5.9 ± 0.3 
 
6 ± 0 
 
6 ± 0 
 
6 ± 0 
 
.32 
 
BiPAP S/T + 
AVAPS 
 
6 ± 0 
 
6 ± 0 
 
5.9 ± 0.3 
 
5.9 ± 0.3 
 
Minute volume 
 
BiPAP S/T 
 
8.7 ± 3.1 
 
9.2 ± 2.2 
 
10.8 ± 1.4 
 
10.6 ± 1.4 
 
.17 
 
BiPAP S/T + 
AVAPS 
 
8.5 ± 2.2 
 
10.5 ± 2.5 
 
11.5 ± 3.1 
 
11.6 ± 1.8 
 
Exhaled tidal volume 
 BiPAP S/T 
 
304 ± 60.6 
 
400.5 ± 
73.9 
 
519 ± 61.4 
 
531.1± 
63.6 
 
.01* 
 
BiPAP S/T + 
AVAPS 
 
298.6 ± 
54.3 
 
606.3 ± 
75.4 
 
626.3 ± 
77.6 
 
617.6 ± 
77.4 
 
Leak BiPAP S/T 
 
9.3 ± 3.8 
 
21 ± 2 
 
11 ± 3 
 
11 ± 3.4 
 
.20 
BiPAP S/T + 
AVAPS 
14 ± 11.2 18.3 ± 3.7 17.5 ± 16 17.5 ± 16 
*Statistically significant (P value <.05).
**
The ANOVA with repeated measures to compare the ability of 
different variables the both groups at 1, 3, 12 hours. 
 
 
Table 2. Duration of hospital stay and time on NIV 
  Group Mean Standard deviation P 
Duration of hospital stay (days) 
 
BiPAP S/T 
 
7.27 
 
2.49 
 
.15 
 
BiPAP S/T + AVAPS 
 
7.09 
 
1.45 
 
Duration of NIV (days) BiPAP S/T 
 
5.81 
 
1.83 
 
.18 
BiPAP S/T + AVAPS 5.36 1.12 
*Statistically significant (P value <.05) 
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Table 3. Initial patient assessment results 
NIV study groups (All 22 patients) Mean SD P 
BMI 
 
BiPAP S/T 
 
26.22 
 
2.87 
 
.99 
 
BiPAP S/T +AVAPS 
 
24.23 
 
2.62 
 
Age (years) 
 
BiPAP S/T 
 
77.55 
 
6.49 
 
.10 
 
BiPAP S/T + AVAPS 
 
79.82 
 
13.53 
 
APACHE II 
 
BiPAP S/T 
 
18.45 
 
2.50 
 
.86 
 
BiPAP S/T + AVAPS 
 
18.55 
 
2.73 
 
Initial GSC 
 
BiPAP S/T 
 
8.36 
 
1.43 
 
1.00 
 
BiPAP S/T + AVAPS 
 
8.36 
 
1.63 
 
Initial pH BiPAP S/T 
 
7.28 
 
0.02 
 
.45 
BiPAP S/T + AVAPS 7.29 0.03 
*Statistically significant (P value <.05). 
A total 22 patients. 11 patients of group BiPAP S/T and 11 patients of group BiPAP S/T +AVAPS 
FIGURES 
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BACKGROUND 
Noninvasive mechanical ventilation (NIV) is used in patients with acute respiratory 
failure for several different etiologies [1]. The heterogeneity of different patient groups leads 
to varying levels of success, with the best results produced in patients with infectious 
exacerbations of COPD and congestive heart failure [2-4]. When NIV is initiated in patients 
with acute respiratory failure due to infectious exacerbations of COPD, ventilatory 
parameters are typically determined based on clinical assessment and changes in blood gases. 
In this manner, NIV support pressures are manually adjusted by an operator [5]. 
One of the limitations of traditional NIV is altered levels of consciousness. However, 
under certain circumstances, especially those produced by hypercapnic conditions [6-8], 
traditional NIV has produced very favorable results, even in patients with hypercapnic 
coma [9]. 
Patients with infectious exacerbations of COPD have obstruction, hyperinflation, air 
trapping, and increased respiratory effort and central respiratory drive. In particular, blood 
pCO2 increases, which, due to its high lipid solubility, readily crosses the blood–brain barrier, 
provoking acidosis in the cerebrospinal fluid and cerebral interstitial tissue [8-13]. 
Previous studies that recommend the use of NIV in patients with altered 
consciousness report a rapid recovery as soon as the ventilatory strategy is established, and 
most recommend early intubation and suspension of treatment if consciousness does not 
quickly normalize [9,10]. Altered levels of consciousness can be assessed using the Glasgow 
Coma Scale (GCS) [14,15], the encephalopathy scoring [16], and the Kelly-Matthay Scale 
(KMS) [17]. Although KMS is specifically designed to assess patients with neurological 
disorders on NIV, it is not commonly used in the emergency unit/ICU. 
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Bilevel positive airway pressure-spontaneous/timed (BiPAP S/T) with average 
volume assured pressure support (AVAPS) allows for setting a fixed tidal volume, and the 
system output automatically adjusts based on variations in inspiratory pressure to ensure the 
predetermined target value. Its long-term benefits have been demonstrated in patients with 
chronic respiratory failure, obstructive sleep apnea, and alveolar hypoventilation 
syndrome [18-20]. 
We designed this study to assess the use of BiPAP S/T with AVAPS as a ventilatory 
strategy in patients with chronic obstructive pulmonary disease (COPD) and hypercapnic 
encephalopathy (GCS < 10) and to compare these results with those from patients treated 
with BiPAP S/T alone, upon immediate arrival in the emergency department/ICU. 
 
METHODS 
Patients 
All patients were admitted between February 2009 and September 2011, and 
permission was obtained from patients or their proxies if patients were unable to answer for 
themselves. The study was approved by the academic and ethics committee of the School of 
Medicine of the Universidad San Francisco de Quito. Three hospitals in Guayaquil, Ecuador 
participated in the study: Hospital Militar, Clinica Panamericana, and Clinica Santa Maria. A 
total of 22 patients were recruited for NIV and divided into two groups of 11. 
Treatment group assignments 
11 patients with infectious exacerbations of COPD and hypercapnic encephalopathy 
with GCS < 10 were designated to receive BiPAP S/T with AVAPS. The control group was 
then selected from patients in the emergency unit with infectious exacerbations of COPD and 
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encephalopathy (GCS < 10). Patients were treated immediately and referred to us by doctors 
who were unaware of the study. Each patient was treated with NIV and was selected 
according to: APACHE II score within 4 points, age within 10 points, pH within 0.04, GCS 
within 2 points, and BMI within 2 points. 
Noninvasive mechanical ventilation: BiPAP S/T with AVAPS 
Ventilatory parameters were initially programmed in the BiPAP S/T mode and 
AVAPS with an inspiratory positive airway pressure (IPAP) maximum programmed into the 
device of 26 cmH2O, to IPAP minimum programmed value of 12 cmH2O and an expiratory 
positive airway pressure (EPAP) of 6 cmH2O. The programmed tidal volume was at 8 to 12 
ml/kg of IBW, and once the patient reached clinical stability and sensory, the target Vt in our 
patients were reprogrammed to 6–8 ml/kg/weight according to manufacturer's specifications, 
the decision was made by the expert physician in charge of patient case dependent, 
respiratory rate was 15 breaths/min, rise time set at 300–400 ms and inspiratory time was at a 
minimum of 0.6 s. Were given supplements O2 via an adapter circuit close to the facemask in 
order to maintain SaO2 above 90%. Patients were maintained on continuous NIV initially. 
Maximum IPAP received delivered, exhaled tidal volume (EVT), Vmin, and leaks 
were monitored through the ventilator software. We used BiPAP Synchrony with AVAPS 
and Autotrak (Respironics Inc., Murrysville, Pennsylvania, USA) and a Mirage IV series 
facemask (Resmed). 
Measurements 
Arterial blood gases were measured at initial values and after 1 hour, 3 hours, 12 
hours and then every 24 hours during NIV; the patient was assessed by a respiratory therapist 
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under close supervision of a physician trained in NIV. Mask use, complications, and 
tolerance were also assessed. 
Disease severity was assessed using the APACHE II score and GCS to determine the 
patient's level of consciousness. Maximum Vt, maximum IPAP, EVT, Vmin, leaks, 
respiratory rate, heart rate, systolic blood pressure, diastolic blood pressure, and IPAP were 
measured upon hospitalization, after 1 hour, 3 hours, and 12 hours, and then every 24 hours 
during NIV. 
Exclusion criteria included facial deformity, obstruction in the upper airway from 
surgery or trauma, alterations of the central nervous system not related to hypercapnic 
encephalopathy, cardiogenic pulmonary edema, pneumothorax, pulmonary 
thromboembolism, hemoptysis or septic shock, emergency intubation due to 
cardiopulmonary arrest, and hemodynamic instability with systolic pressure below 80 mmHg. 
Discontinuation of NIV 
Treatment with NIV was initially used on a continuous regimen based on patient 
tolerance and after normalization of arterial pH > 7.35 ventilation was given in 3-hour blocks. 
The weaning process was initiated when clinical stability was achieved, which was defined as 
respiratory rate less than 24 breaths/min, a heart rate of 90 beats/min, and improved 
awareness and compensation from normalized pH values, with adequate SaO2 in ambient air 
and a low percentage of inspired O2 (3 liters). Once the patient remained stable, NIV was 
discontinued. 
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Control group ventilation parameters: BiPAP S/T 
Ventilatory parameters were initially programmed in BiPAP S/T mode. IPAP was 
programmed at 12 cmH2O, EPAP was programmed at 6 cmH2O. Respiratory rate was set at 
15 breaths/min, rise time set at 300–400 ms, and inspiratory time was at a minimum of 0.6 s. 
Progressively increased levels were IPAP in increments of 2 cmH2O according to the 
discretion of the attending physician. Supplements were added O2 via an adapter circuit close 
to the facemask to maintain SaO2 above 90%. Patients were maintained on continuous NIV 
initially until normalized blood pH ( > 7.35). We monitored EVT, Vmin, and leakage. We 
used BiPAP Synchrony and Autotrak (Respironics Inc.), and two types of facemasks: Mirage 
IV series mask (Resmed) and Series II full facemask(Respironics). We monitored EVT, 
Vmin, and leakage in order to program inspiratory pressure Levels and adjust the mask. 
In addition to ventilatory support, both groups received bronchodilators, intravenous 
corticosteroids, and antibiotic therapy consisting of beta-lactam (piperacillin/tazobactan at 4.5 
g IV every 6 hours) in combination with a new fluoroquinolone (Levofloxacin 500 mg IV 
daily). 
Primary analysis: level of consciousness (Glasgow Coma Scale score). Secondary 
analysis: duration of mechanical ventilation, hospital stay, and progression (exhaled tidal 
volume, inspiratory pressure, and arterial blood gases). 
STATISTICAL ANALYSIS 
All data were expressed as mean ± standard deviation (SD) for continuous variables 
and as percentages for categorical variables. Continuous variables with normal distribution 
were examined using the Kolmogorov-Smirnov test, and were compared using Student's t-
test. For categorical variables, χ2 or Fisher's exact tests were used as appropriate. We used 
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analysis of variance (ANOVA) with repeated measures to compare the ability of different 
variables (pH, pCO2, HCO3, heart rate, respiratory rate, systolic blood pressure, diastolic 
blood pressure, EVT, Vmin, leaks, maximum programmed IPAP, and GCS) to predict the 
outcome of therapy in experimental and control patients. A P value <.05 was considered 
statistically significant. 
RESULTS 
A total of 22 patients were analyzed: 11 in the control group (BiPAP S/T) and 11 in 
the experimental group (BiPAP S/T with AVAPS). The mean age of all patients was 78.68 ± 
10.42 years, mean APACHE II score was 18.50 ± 2.56, 9 patients were women (40.9%) and 
13 were men (59.1%). Four patients were diagnosed with COPD with pneumonia (18.2%) 
and 18 were diagnosed with infectious exacerbations of COPD (81.3%). Sixteen patients 
(73.8%) received NIV in the emergency and ICU. There were no statistically significant 
differences between the two groups in terms of BMI, age, APACHE II score, or initial GCS 
score (Table 1). One patient (4.5%) used a Respironics full face mask, and the other 21 
patients (95.5%) used the Mirage IV series (Resmed). In patients undergoing NIV with 
BiPAP S/T and AVAPS, the programmed tidal volume on AVAPS was 622.73 ± 81.74 ml/kg 
(range: 500–700), with a programmed Vt/kg of 10.26 ± 2.23 ml (range 7.89- 11,83). The 
programmed maximum IPAP values (BiPAP S/T with AVAPS) were: 21.36 ± 3.04 cmH2O 
(initial), 20.82 ± 3.19 cmH2O (1 hour), 19.36 ± 3.80 cmH2O (3 hours), and 19.55 ± 3.45 
cmH2O (12 hours). The ANOVA analysis revealed statistically significant differences in 
favor of AVAPS for pCO2(P = .03), respiratory rate (P = .01), maximum IPAP (P = .005), 
GCS score (P = .00001) (Figure 1), and EVT (P = .01) (Table 2). However, no significant 
differences were observed for length of stay (P = .15) or duration of NIV (P = .18) (Table 3). 
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DISCUSSION 
Comparison with previous studies 
Our study demonstrates that the addition of AVAPS to BiPAP S/T in patients with 
encephalopathy and infectious exacerbations of COPD produces a rapid recovery of 
consciousness (GCS), with early improvement of arterial blood gases as compared to 
conventional ventilation using solely BiPAP S/T. We observed significantly higher IPAP 
values in the BIPAP S/T + AVAPS group than in the group of patients treated solely with 
BIPAP S/T. 
No studies exist in the medical literature describing the benefits of using NIV with 
AVAPS in acute patients. However, in chronic patients with obstructive sleep apnea and 
alveolar hypoventilation syndrome, authors report a rapid improvement in pCO2 and sleep 
quality using this technique [18-20]. Most studies reported in the literature describing 
successful use of NIV in hypercapnic encephalopathy indicate an improvement in GCS 
within only a few hours of initiating NIV, although the vast majority of these are clinical case 
reports or observational studies [6-8,21-26]. 
The goal in our study was, the rapid recovery of consciousness in a group of patients 
undergoing BIPAP S/T + AVAPS (target volume), we scheduled a target volume between 
(500-700ml) in our patients, with a Vt target average 10.26 ± 2.23 ml (range 7.89 to 11.83), 
with peak inspiratory pressures during therapy programmed to 26, once the patient achieved 
clinical stable condition and, in the target Vt our patients were reprogrammed to 6–8 ml/kg/ 
weight according to manufacturer's specifications. The decision was taken by the expert 
physician in charge of patient case-dependent (sensory severity scale or measured initial 
Glasgow). 
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BIPAP mode S/T + AVAPS delivered pressure changes progressively allowing the 
patient to conform much better to those pressures while the target tidal volume is reached. 
Patients with the acute decompensation of COPD, accompanied by an altered mental status 
require rapid correction of alveolar hypoventilation which ensure an adequate tidal volume 
(minute volume) (volume settings between 8–12 ml/kg/weight) for rapid dissemination or 
carbon monoxide swept cerebrospinal fluid and brain and its sensory recovery as early as 
possible. 
Studies examining the use of NIV in hypercapnic encephalopathy indicate that various 
ventilatory modes can be employed at different pressure levels. Gonzales et al [6] used 
BiPAP vision or BiPAP ST-D 30, in which IPAP levels were initially programmed at 12 
cmH2O and increased every 4 hours with an IPAP value in the first hour of 17 + 2 cmH2O. In 
our study, patients on BiPAP S/T with AVAPS had an initial IPAP of 19.82, vs 12.36 in the 
control group. BiPAP S/T with AVAPS achieves the necessary inspiratory pressure level for 
a predetermined tidal volume, ensuring optimal pressure for the patient and facilitating a 
suitable inspiratory volume; this also rapidly overcomes alveolar hypoventilation, corrects 
pCO2 levels, and decreases CO2 levels in the brain so as to improve the patient's level of 
consciousness. Battisti et al. compared manually adjusted pressures with self-adjusting 
pressure support in patients with acute respiratory failure, which produced a decrease in 
pCO2 levels in the latter group [27]. 
Some studies found favorable results in patients using NIV in hypercapnic 
encephalopathy reduction in days of mechanical ventilation [26] reduced risk of nosocomial 
infection [28,29] and avoid intubation [30]. Recently, a pilot study tested the safety and 
efficacy of using an endotracheal tube through BiPAP in patients with a mean GCS of 6, a 
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mean pH of 7.1, and poor management of Secretions, with a success rate of 85% (17/20) 
[31]. 
Answer to the hipothesis 
In our study, initial GCS and pH values were virtually equal between groups. 
Secretions were properly managed, which is essential for preventing technique failure and the 
need for endotracheal intubation. We observed a rapid and significant improvement in arterial 
blood gases and consciousness (GCS) in both groups; however, patients treated with BiPAP 
S/T + AVAPS improved much faster than patients treated with the conventional strategy, 
with a near-complete recovery within 3 hours. The improvement in the BiPAP S/T AVAPS 
group was probably linked to the rapid improvement in EVT and the fact that, in these 
patients, IPAP quickly reached the levels needed for maintaining appropriate tidal volume, 
and hypoventilation was corrected with consequent improvements in alveolar ventilation. 
We observed no complications, gastric distention, or facial deformities, probably due 
to the fact that maximum system pressures did not surpass 20 cmH2O, which is the threshold 
associated with damage to the upper esophageal sphincter and facial structures [32,33]. 
Study limitations 
Our study has certain limitations, including a small number of patients, despite the 
inclusion of three hospitals. In addition, the study was performed by a single research group 
with a long-term experience in NIV, which could create problems when extrapolating the 
results. Finally, it should be emphasized that our patients had a mean pH greater than 7.25, 
whereas other studies of hypercapnic encephalopathy have reported lower values. Other 
studies have also reported higher levels of pCO2 as causing altered levels of consciousness.  
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The lower values of pCO2that we observed could be due to several reasons. Firstly, 
some of our patients live at high altitude places. Gonzalez Garcia et al. [34], showed lower-
than-normal pH and pCO2 values in patients with COPD undergoing effort or exercise [35]. 
Secondly, some of our patients might have had a very low pH with prolonged base excess 
and bicarbonate for patients with COPD. The effects of blood volume, diuretic use, height 
and affecting renal bicarbonate reabsorption have not been assessed [36]. We must also 
consider that patients in both groups experienced a rapid improvement in GCS of 2 points or 
more within 3 hours of starting treatment; a lack of improvement of 2 points could be a 
determining factor for rapid endotracheal intubation, which would obviously constitute an 
invasive procedure [34].  
Finally, our study involved matched case-controls without randomization. Despite 
these limitations, we believe that this study provides valuable information, as it confirms the 
usefulness of NIV in hypercapnic encephalopathy, and upholds BiPAP S/T with AVAPS as a 
strategy that ensures safe and appropriate pressures and tidal volumes, facilitating a rapid 
correction of arterial blood gases, especially pCO2, and thus, minimizing the deleterious 
effects to the brain. 
CONCLUSIONS 
We propose the use of BiPAP S/T with AVAPS as a safe strategy of noninvasive 
ventilatory treatment in patients with exacerbations of COPD and hypercapnic 
encephalopathy (GCS < 10), with the caveat that these patients should be treated in units with 
ample experience and under close surveillance. 
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ABBREVIATIONS 
APACHE II: Acute physiology and chronic health evaluation II; AVAPS: Average 
volume assured pressure support; BiPAP (S/T): Bilevel positive airway pressure 
(spontaneous/timed); EPAP: Expiratory positive airway pressure; EVT: Exhaled tidal 
volume; GCS: Glasgow Coma Scale; IPAP: Inspiratory positive airway pressure; NIV: 
Noninvasive mechanical ventilation; pCO2: Partial pressure of carbon dioxide; Vmin: Minute 
volume; Vt: Tidal volume; COPD: Chronic obstructive pulmonary disease. 
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